share_log

盘中速览 | 港股高开低走,医药股领涨,百济神州涨近10%

Intraday Quick View | Hong Kong stocks open high and go low, medical stocks lead the rise, BeiGene, Ltd. is up nearly 10%

富途資訊 ·  Aug 5, 2022 10:44

According to Futu News on August 5, Hong Kong stocks opened high and left low today. as of press time, the Hang Seng Index fell 0.15%, the Hang Seng Technology Index fell 0.02%, and the State-owned Enterprises Index fell 0.22%.

Most of the science and Internet stocks are weak.Tencent and BABA fell by more than 2%, Kuaishou Technology fell by more than 1%, JD.com and Meituan fell slightly, and Bilibili Inc. rose slightly.

Pharmaceutical stocks rose collectively.BeiGene, Ltd. rose nearly 10%, Kangfang Biology and Keji Pharmaceutical rose more than 7%, and Zai Lab Limited rose more than 5%.

Some auto stocks rose.XPeng Inc. rose nearly 4%, NIO Inc. rose more than 2%, and Great Wall Motor rose slightly.

Inner housing stocks pull upXuhui holding Group rose by more than 8%, Metro Development by more than 6%, and R & F Real Estate by more than 3%.

Property management stocks rose.Xuhui Yongsheng service rose nearly 10%, Jinke service rose more than 8%, and Sunac Services rose more than 5%.

Individual stocks$BABA-SW (09988.HK) $After the performance, it fell by nearly 3%, and the turnover exceeded HK $1.7 billion. After the results were announced, CICC issued a research report to maintain its "outperform industry" rating, with a target price of HK $137.

$INNOVENT BIO (01801.HK) $At one point, it rose by more than 10%, but now it has risen by more than 6% as of press time. On the news side, the company has reached a multi-project strategic cooperation and licensing agreement with Sanofi Group, and will be invested in Sanofi at a premium of 600 million euros.

Hua Hong Semiconductor (01347.HK) $led chip stocks up, and is now up more than 4%. The agency said that the localization of the domestic semiconductor industry is expected to accelerate.

$BeiGene, Ltd. (06160.HK) $After the performance soared nearly 10%, the company achieved outstanding results in the first half of 2022, with product revenue of US $566.1 million, an increase of 131.3% over the same period last year.

Edit / somer

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment